📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-03 17:56
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
1 announcement match the current filters (relevance ≥ 5).
60% YoY Revenue Growth in Q1 FY27; Aatmaj Acquires Anand Hospital & Lab
Aatmaj Healthcare reported a strong Q1 FY27 with revenue growing 60% YoY to ₹8.13 Cr and profit before tax & depreciation surging 170% to ₹1.52 Cr. The company expanded its network by acquiring Anand Hospital, Laboratory, and Pharmacy in Vadodara, which is projected to contribute ₹9-9.5 Cr in revenue for FY27. Additionally, it launched new CTVS and IVF specialty departments and secured PM-JAY empanelment for its Badnawar facility. Management also reported a 5% recovery of old debt, improving liquidity.
Confidence: HIGH
What changedThe company has transitioned from organic operations to aggressive inorganic expansion with a new hospital acquisition and the launch of high-margin specialty departments.
Why it mattersThe acquisition of Anand Hospital represents a significant capacity addition (projected revenue is ~21% of TTM revenue), while specialty departments like IVF and CTVS diversify the revenue mix away from low-margin government schemes.
Q1 FY27 Revenue: ₹8.13 CrYoY Revenue Growth: 60%Anand Hospital Expected Revenue: ₹9-9.5 CrAcquisition Revenue vs TTM Revenue: ~21%Old Debt Recovery: 5%
📅 Short termThe strong YoY growth and acquisition news are likely to be viewed positively by the market, potentially improving sentiment for this micro-cap stock.
📈 Long termThe structural shift toward a multi-specialty hospital chain and increased bed capacity (330 beds) provides a platform for scaling, though high debt (D/E 0.41) and PM-JAY receivable cycles remain key monitors.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependency on government PM-JAY scheme payments
- Integration risks of newly acquired hospital and pharmacy units
- High debt relative to small market cap
Key Highlights
Q1 FY27 revenue increased 60% YoY to ₹8.13 Cr from ₹5.05 Cr in the previous year.
Profit before tax and depreciation rose 170% YoY to ₹1.52 Cr, improving margins to 18.76%.
Acquisition of Anand Hospital and associated units is expected to generate ₹9-9.5 Cr in revenue for FY27.
Bed capacity has expanded 153.8% from 130 to 330 beds through recent strategic initiatives.
Successfully recovered approximately 5% of old debt during the first quarter to improve working capital.
👀 What to Watch
Monitor the integration of the newly acquired Anand Hospital and the revenue ramp-up from the new CTVS and IVF departments to see if they meet the ₹9 Cr+ annual target.
